Navigation Links
Osseon Receives Second Patent Allowance for Minimally Invasive Vertebral Compression Fracture Treatment Devices

SANTA ROSA, Calif., Oct. 4 /PRNewswire/ -- Osseon Therapeutics, Inc., a biomedical device company based in Santa Rosa, California, received its second patent Notice of Allowance (NOA) for its spinal vertebral compression fracture (VCF) technology.  The company, which was started in 2006, now has two allowed and twelve additional patent applications pending in the United States, and several others throughout the world for spinal therapies and devices.  

The company has been marketing its FDA and CE Mark cleared "Osseoplasty™" system in the U.S. and Europe, since February, 2009 and February, 2010, respectively.  The proprietary Osseoplasty™ procedure has been performed in over 1,100 patients in the U.S. and Europe.

According to John Stalcup, Ph.D., President and CEO of Osseon, "This second patent allowance for Osseon's spinal VCF technology is another cornerstone for the company's intellectual property foundation.  We continue to strengthen our intellectual property position and strive to obtain additional patents in the future on various aspects of the Osseoflex® steerable and curvable needle and the novel methods for bone cement delivery, which enable a safe, effective, and minimally invasive approach for spine disease treatment."

ABOUT Osseon Therapeutics, Inc.

About Osseon

Osseon Therapeutics, Inc. focuses on bringing to market alternative minimally invasive treatments for degenerative bone and joint disease. Headquartered in Santa Rosa, CA, the company's groundbreaking technology and delivery system provides comparable or better efficacy and safety than other commercial solutions while offering significant advantages in efficiency and cost. By improving the treatment of compression fractures within the thoracic and lumbar vertebral spine, Osseon offers alternative solutions to patients suffering from these maladies, as well as the physicians and medical facilities that treat them. Its first-generation products have received both FDA clearance and the CE Mark for product distribution in the United States and European Union.  For more information, visit our web site at

Osseon®  and Osseoflex® are registered trademarks, and Osseoplasty™ is a trademark of Osseon Therapeutics, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners.

SOURCE Osseon Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Osseon Receives Patent Allowance for Novel Spinal VCF Treatment Devices
2. Osseon Therapeutics Demonstrates to the European Medical Community How to Think Outside The Balloon When Treating Vertebral Compression Fractures
3. Osseon Launches in Europe
4. Prognosis Health Information Systems ChartAccess 4.0 Receives ONC-ATCB 2011/2012 Certification
5. Mylan Receives Approval for Fludarabine Phosphate Injection, USP
6. WATCHMAN® Receives German Reimbursement Coverage
7. Lingohocken Fire Company Receives PAD Donation After Recent Rescue at Fox Heath Farm
8. Abbott Receives FDA Market Clearance for Next-Generation Contact Lens Disinfecting Solution
9. Advanced Life Sciences Receives $1.5 Million From Exercise of Unit Warrants and Secures Financing Commitment
10. China Shenghuo Receives Notice from NYSE Amex LLC Regarding Listing Standards
11. Progenika Receives CE Mark for First DNA Chip to Detect Mutations in Lipoprotein Lipase (LPL) Gene
Post Your Comments:
(Date:11/26/2015)... 2015 --> ... blends immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer. ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... immunotherapy with Bremachlorin-photodynamic therapy for advanced cancer.   ... that immunotherapy can be efficiently combined with photodynamic therapy ...
(Date:11/26/2015)... November 26, 2015 --> ... use SyMRI to find optimal contrast weighting of MRI ... and has signed a research agreement with SyntheticMR in order ... Using SyMRI, it is possible to generate multiple contrast images ... the patient has left, thus making it possible to both ...
(Date:11/26/2015)... , November 26, 2015 3D ... by 2022, according to a new report by Grand View ... Kidney Disease (CKD) which demands kidney transplantation is expected to ... cost effective substitute for organ transplantation. --> 3D ... by 2022, according to a new report by Grand View ...
Breaking Medicine Technology:
(Date:11/29/2015)... ... November 29, 2015 , ... Effective immediately, every single IguanaMed scrub style will ... Friday Target is offering a “Buy One Scrub Set, Get the 2nd Scrub Set ... purchase IguanaMed at a discounted price. , IguanaMed’s mission is to outfit ...
(Date:11/28/2015)... ... ... Beginning November 30th at 6:00 a.m. EST until 11:59 p.m. EST, customers ... up to 20% off orders $80 or more to free gifts with purchases, there will ... As a competitive e-commerce website for skin care and cosmetic needs, customers will save on ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article ... way that they are handling security in light of the recent terrorist attacks in ... an attempt to stop an attack from reaching U.S. soil. Especially around special events ...
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just ... is offering customers 10% off of their purchase of lice treatment product. In addition, ... price. According to a company spokesperson. “Finding lice is a sure way to ruin ...
(Date:11/27/2015)... Wilmington, DE (PRWEB) , ... November 27, 2015 ... ... a member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as ... is an independent group of Microsoft Dynamics SL software users, partners, industry experts ...
Breaking Medicine News(10 mins):